Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome: A Decision Analysis.


Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 8 4 2020
medline: 25 11 2020
entrez: 8 4 2020
Statut: ppublish

Résumé

Fetal aortic valvuloplasty (FAV) may prevent progression of midgestation aortic stenosis to hypoplastic left heart syndrome. However, FAV has well-established risks, and its survival benefit remains unknown. Our primary aim was to determine whether FAV for midgestation aortic stenosis increases survival from fetal diagnosis to age 6 years. We performed a retrospective analysis of 143 fetuses who underwent FAV from 2000 to 2017 and a secondary analysis of the Pediatric Heart Network Single Ventricle Reconstruction trial. Using these results, we developed a decision model to estimate probability of transplant-free survival from fetal diagnosis to age 6 years and postnatal restricted mean transplant-free survival time. FAV was technically successful in 84% of 143 fetuses with fetal demise in 8%. Biventricular circulation was achieved in 50% of 111 live-born infants with successful FAV but in only 16% of the 19 patients with unsuccessful FAV. The model projected overlapping probabilities of transplant-free survival to age 6 years at 75% (95% CI, 67%-82%) with FAV versus 72% (95% CI, 61%-82%) with expectant fetal management, resulting in a restricted mean transplant-free survival time benefit of 1.2 months. When limiting analyses to the improved FAV experience since 2009 to reflect current practice, (probability of technical success [94%], fetal demise [4%], and biventricular circulation [66%]), the model projected that FAV increased the probability of survival to age 6 years to 82% (95% CI, 73%-89%). Expectant management is favored if risk of fetal demise exceeded 12% or probability of biventricular circulation fell below 26%, but FAV remained favored over plausible recent range of technical success. Our model suggests that FAV provides a modest, medium-term survival benefit over expectant fetal management. Appropriate patient selection and low risk of fetal demise with FAV are critical factors for obtaining a survival benefit.

Sections du résumé

BACKGROUND
Fetal aortic valvuloplasty (FAV) may prevent progression of midgestation aortic stenosis to hypoplastic left heart syndrome. However, FAV has well-established risks, and its survival benefit remains unknown. Our primary aim was to determine whether FAV for midgestation aortic stenosis increases survival from fetal diagnosis to age 6 years.
METHODS AND RESULTS
We performed a retrospective analysis of 143 fetuses who underwent FAV from 2000 to 2017 and a secondary analysis of the Pediatric Heart Network Single Ventricle Reconstruction trial. Using these results, we developed a decision model to estimate probability of transplant-free survival from fetal diagnosis to age 6 years and postnatal restricted mean transplant-free survival time. FAV was technically successful in 84% of 143 fetuses with fetal demise in 8%. Biventricular circulation was achieved in 50% of 111 live-born infants with successful FAV but in only 16% of the 19 patients with unsuccessful FAV. The model projected overlapping probabilities of transplant-free survival to age 6 years at 75% (95% CI, 67%-82%) with FAV versus 72% (95% CI, 61%-82%) with expectant fetal management, resulting in a restricted mean transplant-free survival time benefit of 1.2 months. When limiting analyses to the improved FAV experience since 2009 to reflect current practice, (probability of technical success [94%], fetal demise [4%], and biventricular circulation [66%]), the model projected that FAV increased the probability of survival to age 6 years to 82% (95% CI, 73%-89%). Expectant management is favored if risk of fetal demise exceeded 12% or probability of biventricular circulation fell below 26%, but FAV remained favored over plausible recent range of technical success.
CONCLUSIONS
Our model suggests that FAV provides a modest, medium-term survival benefit over expectant fetal management. Appropriate patient selection and low risk of fetal demise with FAV are critical factors for obtaining a survival benefit.

Identifiants

pubmed: 32252549
doi: 10.1161/CIRCOUTCOMES.119.006127
pmc: PMC7737668
mid: NIHMS1569840
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e006127

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007572
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Circulation. 2014 May 20;129(20):2013-20
pubmed: 24705119
Am J Perinatol. 2014 Aug;31(7):629-36
pubmed: 24922056
Pediatr Cardiol. 2015 Oct;36(7):1502-9
pubmed: 25972285
Ultrasound Obstet Gynecol. 2018 Aug;52(2):212-220
pubmed: 28543953
J Am Coll Cardiol. 2015 Jul 28;66(4):388-99
pubmed: 26205597
Circulation. 2014 Aug 19;130(8):638-45
pubmed: 25052401
Am Heart J. 1992 Jun;123(6):1712-3
pubmed: 1595559
BMC Med Res Methodol. 2013 Dec 07;13:152
pubmed: 24314264
Biometrics. 2016 Mar;72(1):215-21
pubmed: 26302239
Ultrasound Obstet Gynecol. 2006 Jul;28(1):47-52
pubmed: 16795115
J Pediatr. 2005 Oct;147(4):535-9
pubmed: 16227042
JAMA Cardiol. 2017 Nov 1;2(11):1179-1180
pubmed: 28877311
Am J Cardiol. 2000 May 15;85(10):1230-3
pubmed: 10802006
Circulation. 2009 Oct 13;120(15):1482-90
pubmed: 19786635
Heart. 1997 Mar;77(3):205-10
pubmed: 9093035
N Engl J Med. 2010 May 27;362(21):1980-92
pubmed: 20505177
Ann Intern Med. 2015 Jul 21;163(2):127-34
pubmed: 26054047
Ultrasound Obstet Gynecol. 2016 Sep;48(3):373-81
pubmed: 26843026
Pediatrics. 2012 Feb;129(2):e370-6
pubmed: 22232310
Circulation. 2018 May 22;137(21):2246-2253
pubmed: 29437119
Ultrasound Obstet Gynecol. 1995 Feb;5(2):90-1
pubmed: 7719873
Br Heart J. 1991 May;65(5):256-8
pubmed: 2039669
Am J Cardiol. 2011 Aug 15;108(4):556-60
pubmed: 21624551
Circulation. 2010 Mar 16;121(10):1256-63
pubmed: 20231543
Ultrasound Obstet Gynecol. 2000 Apr;15(4):271-8
pubmed: 10895443
Circulation. 2004 Oct 12;110(15):2125-31
pubmed: 15466631
J Am Coll Cardiol. 2010 Nov 16;56(21):1740-9
pubmed: 21070926
Ultrasound Obstet Gynecol. 2015 Jun;45(6):657-63
pubmed: 25042627
Bioethics. 2015 Jul;29(6):413-23
pubmed: 25395144
Circulation. 2006 Mar 21;113(11):1401-5
pubmed: 16534003

Auteurs

Sarah S Pickard (SS)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).
Departments of Pediatrics (S.S.P., E.B., J.W.N., W.T., D.P., R.C., K.G.F.), Harvard Medical School, Boston, MA.

John B Wong (JB)

Division of Clinical Decision Making, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA (J.B.W.).

Emily M Bucholz (EM)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).
Departments of Pediatrics (S.S.P., E.B., J.W.N., W.T., D.P., R.C., K.G.F.), Harvard Medical School, Boston, MA.

Jane W Newburger (JW)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).
Departments of Pediatrics (S.S.P., E.B., J.W.N., W.T., D.P., R.C., K.G.F.), Harvard Medical School, Boston, MA.

Wayne Tworetzky (W)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).
Departments of Pediatrics (S.S.P., E.B., J.W.N., W.T., D.P., R.C., K.G.F.), Harvard Medical School, Boston, MA.

Terra Lafranchi (T)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).

Carol B Benson (CB)

Departments of Radiology (C.B.B.), Brigham and Women's Hospital, Boston, MA.

Louise E Wilkins-Haug (LE)

Obstetrics and Gynecology (L.E.W.-H.), Brigham and Women's Hospital, Boston, MA.
Obstetrics and Gynecology, (L.E.W.-H.), Harvard Medical School, Boston, MA.

Diego Porras (D)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).
Departments of Pediatrics (S.S.P., E.B., J.W.N., W.T., D.P., R.C., K.G.F.), Harvard Medical School, Boston, MA.

Ryan Callahan (R)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).
Departments of Pediatrics (S.S.P., E.B., J.W.N., W.T., D.P., R.C., K.G.F.), Harvard Medical School, Boston, MA.

Kevin G Friedman (KG)

Department of Cardiology, Boston Children's Hospital, MA (S.S.P., E.M.B., J.W.N., W.T., T.L., D.P., R.C., K.G.F.).
Departments of Pediatrics (S.S.P., E.B., J.W.N., W.T., D.P., R.C., K.G.F.), Harvard Medical School, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH